GMAB: Late-stage pipeline advances and strong growth set up major Q4 data readouts in oncology
Multiple late-stage assets are advancing, with six new phase III trials and strong financial growth. Petosemtamab and EPKINLY are poised for major data readouts in Q4, potentially setting new standards in head and neck, colorectal, and B-cell cancers.Based on Genmab A/S [GMAB] Morgan Stanley 24th A…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.